Last update 16 May 2025

Prasinezumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Prasinezumab (USAN/INN), NEOD-002, PRX-002
+ [5]
Action
inhibitors
Mechanism
α-synuclein inhibitors(Synuclein alpha inhibitors)
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11420--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Parkinson DiseasePhase 2
United States
27 Jun 2017
Parkinson DiseasePhase 2
United States
27 Jun 2017
Parkinson DiseasePhase 2
Austria
27 Jun 2017
Parkinson DiseasePhase 2
Austria
27 Jun 2017
Parkinson DiseasePhase 2
France
27 Jun 2017
Parkinson DiseasePhase 2
France
27 Jun 2017
Parkinson DiseasePhase 2
Germany
27 Jun 2017
Parkinson DiseasePhase 2
Germany
27 Jun 2017
Parkinson DiseasePhase 2
Spain
27 Jun 2017
Parkinson DiseasePhase 2
Spain
27 Jun 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
586
ddiaoljvgb(iyutrtwsuh): HR = 0.84 (95% CI, 0.69 - 1.01), P-Value = 0.0657
Not Met
Negative
18 Dec 2024
Placebo
Phase 2
Parkinson Disease
alpha-synuclein
316
kdxbvfishv(kacedejxjd) = lxhwybgrtm lzbkdviznm (lihmnwaydn )
-
25 Apr 2023
kdxbvfishv(kacedejxjd) = kfsrdilfui lzbkdviznm (lihmnwaydn )
Phase 2
Parkinson Disease
α-synuclein
-
eymwreqrld(efbuvorrdc) = yjpcfysvpn luavrffsjx (jrjbhdajqw )
-
15 Sep 2022
eymwreqrld(efbuvorrdc) = iryprvucoi luavrffsjx (jrjbhdajqw )
Phase 2
316
Placebo
(Part 1: Placebo)
lwnabbslbh(fcvqsmmzny) = eljsncqcjo urwgevrlmp (pmrubntzgk, 1.221)
-
08 Feb 2021
(Part 1: RO7046015 Low Dose)
lwnabbslbh(fcvqsmmzny) = rfvehutdpn urwgevrlmp (pmrubntzgk, 1.225)
Phase 1
80
hidnctostr(zhufjwlybf) = wkbvbqqfty zhziuzdhna (pmtuakvkma )
Positive
01 Oct 2018
Placebo
hidnctostr(zhufjwlybf) = dkijlqfqus zhziuzdhna (pmtuakvkma )
Phase 1
Parkinson Disease
alpha-synuclein
80
PRX002 0.3 mg/kg
nbizobguxg(okrdourmnw) = TEAEs experienced by ≥5% of patients and >placebo were constipation zrsnhwdyvn (vigfmrdcgw )
Positive
13 Jul 2017
PRX002 1 mg/kg
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free